<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="84978">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01998971</url>
  </required_header>
  <id_info>
    <org_study_id>CR103015</org_study_id>
    <secondary_id>54767414MMY1001</secondary_id>
    <secondary_id>2013-003491-12</secondary_id>
    <nct_id>NCT01998971</nct_id>
  </id_info>
  <brief_title>A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma</brief_title>
  <official_title>An Open-Label, Multicenter, Phase 1b Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Regimens for the Treatment of Subjects With Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and dose regimen of
      daratumumab when administered in combination with various treatment regimens for the
      treatment of multiple myeloma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label (identity of assigned study drug will be known) study to evaluate the
      safety, tolerability, and dose of daratumumab when administered in combination with various
      treatment regimens for different settings of multiple myeloma. The various treatment
      regimens to be combined with daratumumab in this study include Velcade-dexamethasone (VD),
      Velcade-melphalan-prednisone (VMP), Velcade-thalidomide-dexamethasone (VTD),
      pomalidomide-dexamethasone (Pom-dex), carfilzomib-dexamethasone (CFZ-dex) and
      carfilzomib-lenalidomide-dexamethasone (KRd). Approximately 250 patients (approximately 12
      subjects per VTD and VMP backbone treatment regimen, 6 for the VD regimen, up to 100
      subjects in the Pom-dex regimen, 80 for the CFZ-dex regimen [10 subjects will receive a
      single-dose of daratumumab and the remaining subjects will receive a split-dose of
      daratumumab], and up to 40 for the KRd regimen) will be enrolled in this study.The study
      will consist of screening, treatment, and follow-up phases. Treatment will extend to either
      the planned treatment duration for a maximum of 1 year (in Velcade-dexamethasone,
      Velcade-melphalan-prednisone, Velcade-thalidomide-dexamethasone regimens and KRd regimens),
      or until disease progression (in the Pom-dex and CFZ-dex regimen). Follow-up will continue
      until the study ends (approximately 15 months after the last patient receives the first dose
      of daratumumab). Serial pharmacokinetic (study of what a drug does to the body) blood
      samples will be collected. Clinical efficacy outcomes and safety will be monitored
      throughout the study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 18, 2014</start_date>
  <completion_date type="Anticipated">October 27, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants affected by adverse events by MedDRA system organ class (SOC) and Preferred term (PT)</measure>
    <time_frame>Up to 30 days after the last dose of study medication</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants affected by dose-limiting toxicities</measure>
    <time_frame>Up to 30 days after the last dose of study medication</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration of daratumumab</measure>
    <time_frame>Up to post-treatment visit Week 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with generation of antibodies to daratumumab</measure>
    <time_frame>Up to post-treatment visit Week 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response rate</measure>
    <time_frame>Up to 15 months after last patient receives first dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>Up to 15 months after last patient receives first dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Up to 15 months after last patient receives first dose of study drug</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Daratumumab + VD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daratumumab will be administered with Velcade-dexamethasone (VD).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daratumumab + VMP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daratumumab will be administered with Velcade-melphalan-prednisone (VMP).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daratumumab + VTD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daratumumab will be administered with Velcade-thalidomide-dexamethasone (VTD).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daratumumab + Pom-dex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daratumumab will be administered with pomalidomide-dexamethasone (Pom-dex).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daratumumab + CFZ-dex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daratumumab will be administered with carfilzomib (CFZ)-dexamethasone (CFZ-dex) regimen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daratumumab + KRd</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daratumumab will be administered with carfilzomib- lenalidomide-dexamethasone (KRd) regimen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daratumumab</intervention_name>
    <description>Administered by intravenous infusion in combination with the applicable backbone treatment.</description>
    <arm_group_label>Daratumumab + VD</arm_group_label>
    <arm_group_label>Daratumumab + VMP</arm_group_label>
    <arm_group_label>Daratumumab + VTD</arm_group_label>
    <arm_group_label>Daratumumab + Pom-dex</arm_group_label>
    <arm_group_label>Daratumumab + CFZ-dex</arm_group_label>
    <arm_group_label>Daratumumab + KRd</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Velcade</intervention_name>
    <description>Administered subcutaneously in accordance with product labeling and local standards.</description>
    <arm_group_label>Daratumumab + VD</arm_group_label>
    <arm_group_label>Daratumumab + VMP</arm_group_label>
    <arm_group_label>Daratumumab + VTD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pomalidomide</intervention_name>
    <description>Administered orally in accordance with product labeling and local standards.</description>
    <arm_group_label>Daratumumab + Pom-dex</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Administered intravenously or orally in accordance with product labeling and local standards.</description>
    <arm_group_label>Daratumumab + VD</arm_group_label>
    <arm_group_label>Daratumumab + VTD</arm_group_label>
    <arm_group_label>Daratumumab + Pom-dex</arm_group_label>
    <arm_group_label>Daratumumab + CFZ-dex</arm_group_label>
    <arm_group_label>Daratumumab + KRd</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Administered orally in accordance with product labeling and local standards.</description>
    <arm_group_label>Daratumumab + VMP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Administered intravenously or orally in accordance with product labeling and local standards.</description>
    <arm_group_label>Daratumumab + VMP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide</intervention_name>
    <description>Administered orally in accordance with product labeling and local standards.</description>
    <arm_group_label>Daratumumab + VTD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diphenhydramine</intervention_name>
    <description>Administered in prophylactic doses intravenously (or equivalent) in accordance with product labeling and local standards.</description>
    <arm_group_label>Daratumumab + VD</arm_group_label>
    <arm_group_label>Daratumumab + VMP</arm_group_label>
    <arm_group_label>Daratumumab + VTD</arm_group_label>
    <arm_group_label>Daratumumab + Pom-dex</arm_group_label>
    <arm_group_label>Daratumumab + CFZ-dex</arm_group_label>
    <arm_group_label>Daratumumab + KRd</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen</intervention_name>
    <description>Administered in prophylactic doses by mouth in accordance with product labeling and local standards.</description>
    <arm_group_label>Daratumumab + VD</arm_group_label>
    <arm_group_label>Daratumumab + VMP</arm_group_label>
    <arm_group_label>Daratumumab + VTD</arm_group_label>
    <arm_group_label>Daratumumab + Pom-dex</arm_group_label>
    <arm_group_label>Daratumumab + CFZ-dex</arm_group_label>
    <arm_group_label>Daratumumab + KRd</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carfilzomib</intervention_name>
    <description>Administered intravenously in accordance with product labeling and local standards.</description>
    <arm_group_label>Daratumumab + CFZ-dex</arm_group_label>
    <arm_group_label>Daratumumab + KRd</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Administered orally in accordance with product labeling and local standards.</description>
    <arm_group_label>Daratumumab + KRd</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Montelukast</intervention_name>
    <description>Administered intravenously or orally only with the first daratumumab dose in accordance with product labeling and local standards.</description>
    <arm_group_label>Daratumumab + CFZ-dex</arm_group_label>
    <arm_group_label>Daratumumab + KRd</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of symptomatic multiple myeloma and measurable secretory disease

          -  For carfilzomib-lenalidomide-dexamethasone (KRd) regimen: newly diagnosed myeloma.
             For carfilzomib-dexamethasone (CFZ-dex) regimen: relapsed or refractory disease

          -  Eastern Cooperative Oncology Group performance status score of 0, 1, or 2

          -  Pretreatment clinical laboratory values must meet protocol-defined parameters during
             the screening phase

        Exclusion Criteria:

          -  Previously received daratumumab or other anti-CD38 therapies

          -  Diagnosis of primary amyloidosis, monoclonal gammopathy of undetermined significance,
             smoldering multiple myeloma, Waldenström's disease, or other conditions in which IgM
             M-protein is present in the absence of a clonal plasma cell infiltration with lytic
             bone lesions

          -  Peripheral neuropathy or neuropathic pain Grade 2 or higher

          -  Prior or concurrent invasive malignancy (other than multiple myeloma) within 5 years
             of study start

          -  Exhibiting clinical signs of meningeal involvement of multiple myeloma

          -  Known chronic obstructive pulmonary disease, persistent asthma, or a history of
             asthma within 2 years

          -  Seropositive for human immunodeficiency virus, hepatitis B, or hepatitis C

          -  Any concurrent medical or psychiatric condition or disease that is likely to
             interfere with the study procedures or results, or that in the opinion of the
             investigator, would constitute a hazard for participating in this study

          -  Clinically significant cardiac disease

          -  Plasma cell leukemia or POEMS (polyneuropathy, organomegaly, endocrinopathy,
             monoclonal protein, and skin changes) syndrome
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Use link at the bottom of the page to see if you qualify for an enrolling site (see list). If you still have questions:</last_name>
    <email>JNJ.CT@sylogent.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Emory University - Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NYU School of Medicine, NYU Langone Medical Center, Ambulatory Care Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10023</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Abramson Cancer Center, University of Pennslyvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Claude Huriez</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hotel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital du Haut Lévêque</name>
      <address>
        <city>Pessac</city>
        <zip>33600</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic I Provincial</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica Universitaria de Navarra</name>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari La Fe de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://pam.sylogent.com/cr/CR103015</url>
    <description>To learn how to participate in this trial please click here.</description>
  </link>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 31, 2017</lastchanged_date>
  <firstreceived_date>November 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple myeloma</keyword>
  <keyword>Daratumumab</keyword>
  <keyword>JNJ-54767414</keyword>
  <keyword>Velcade-dexamethasone</keyword>
  <keyword>Velcade-melphalan-prednisone</keyword>
  <keyword>Velcade-thalidomide-dexamethasone</keyword>
  <keyword>Pomalidomide-dexamethasone</keyword>
  <keyword>Carfilzomib-dexamethasone</keyword>
  <keyword>Carfilzomib-lenalidomide-dexamethasone</keyword>
  <keyword>Anti-CD38 Monoclonal Antibody</keyword>
  <keyword>Immunomodulatory drug</keyword>
  <keyword>IMiD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Pomalidomide</mesh_term>
    <mesh_term>Daratumumab</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Promethazine</mesh_term>
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
